Cullinan Therapeutics (CGEM) Stock Price, News & Analysis

Company Overview

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $14.09 to $15.13
• 50-Day Range: $12.75 to $16.30
• 52-Week Range: $5.68 to $16.74
• Volume: 1.23 million shs
• Average Volume: 749,635 shs
• Market Capitalization: $904.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $29.89
• Consensus Rating: Moderate Buy

Cullinan Therapeutics Stock Analysis - MarketRank™

Cullinan Therapeutics scored higher than 72% of companies evaluated by MarketBeat, and ranked 194th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cullinan Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Cullinan Therapeutics has a consensus price target of $29.89, representing about 103.0% upside from its current price of $14.72.

Amount of Analyst Coverage

Cullinan Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cullinan Therapeutics are expected to grow in the coming year, from ($3.06) to ($2.87) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cullinan Therapeutics is -4.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cullinan Therapeutics is -4.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cullinan Therapeutics has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CGEM.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cullinan Therapeutics does not currently pay a dividend.

Dividend Growth

Cullinan Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.65

News Sentiment

Cullinan Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Cullinan Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for CGEM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

5 people have added Cullinan Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Cullinan Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,230,319.00 in company stock.

Percentage Held by Insiders

7.16% of the stock of Cullinan Therapeutics is held by insiders.

Percentage Held by Institutions

86.31% of the stock of Cullinan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CGEM Stock Analysis - Frequently Asked Questions

How have CGEM shares performed this year?

Cullinan Therapeutics' stock was trading at $10.35 at the beginning of 2026. Since then, CGEM shares have increased by 42.2% and is now trading at $14.72.

How were Cullinan Therapeutics' earnings last quarter?

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) issued its earnings results on Thursday, May, 7th. The company reported ($0.75) earnings per share for the quarter, beating analysts' consensus estimates of ($0.84) by $0.09.

When did Cullinan Therapeutics IPO?

Cullinan Therapeutics (CGEM) raised $232 million in an initial public offering (IPO) on Friday, January 8th 2021. The company issued 11,900,000 shares at $19.00-$20.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

Who are Cullinan Therapeutics' major shareholders?

Top institutional shareholders of Cullinan Therapeutics include Dimensional Fund Advisors LP (1.47%), Bank of New York Mellon Corp (0.23%), Assenagon Asset Management S.A. (0.23%) and Y Intercept Hong Kong Ltd (0.16%). Insiders that own company stock include Lynx1 Capital Management Lp, Nadim Ahmed, Jennifer Michaelson, Corrine Savill, Jeffrey Alan Jones, Jacquelyn L Sumer, Mary Kay Fenton and Jeffrey Trigilio.
View institutional ownership trends.

How do I buy shares of Cullinan Therapeutics?

Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cullinan Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cullinan Therapeutics investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Visa (V).

Company Calendar

• Today: 5/07/2026
• Last Earnings: 5/07/2026
• Next Earnings (Estimated): 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CGEM
• CIK: 1789972
• Web: www.cullinanoncology.com
• Phone: 617-410-4650
• Fax: N/A
• Employees: 30
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Cullinan Therapeutics: $29.89
• High Price Target: $38.00
• Low Price Target: $22.00
• Potential Upside/Downside: +103.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$219.88 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -46.19%
• Return on Assets: -43.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.25
• Quick Ratio: 10.25

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.92 per share
• Price / Book: 2.13

Miscellaneous

• Outstanding Shares: 61,450,000
• Free Float: 57,051,000
• Market Cap: $904.54 million
• Optionable: Optionable
• Beta: -0.09